NCT00268151终止1 期
Phase I Study of Oxaliplatin (Eloxatin) and Capecitabine (Xeloda) and Concurrent Radiation Therapy (XELOX-RT) in Non-Small Cell Lung Cancer
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 24
- 试验地点
- 2
研究概览
简要总结
The purpose of this study is to determine the most suitable dose of Oxaliplatin that can be safely given in combination with a low fixed dose of Capecitabine and a limited volume of radiation in patients with non-small cell lung cancer.
详细描述
The purpose of this study is to determine the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of Oxaliplatin in combination with Capecitabine and radiation in subjects with non-small cell lung cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •histologically proven non-small cell lung cancer
- •inoperable Stage III A or B NSCLC
- •must have measurable disease by RECIST criteria
- •no more than one prior chemotherapy for advanced disease
- •ECOG Performance Status of 0, 1, or 2
- •must be able to swallow pills or have a working gastric feeding tube and no evidence of malabsorption
- •negative serum beta-HCG test and under active contraception (for females of childbearing potential)
- •no known allergies to any of the study drugs
- •willingness to sign an informed consent
排除标准
- •women who are pregnant or breastfeeding
- •ANC of less than 1500/mm3
- •platelet count of less than 100,000/mm3
- •estimated creatinine clearance of less than 50 cc/min (as measured by the Cockcroft-Gault equation)
- •bilirubin of less than 2mg/dl
- •SGPT of greater than 2x nl
- •peripheral neuropathy of Grade 2 or higher
- •more than one previous chemotherapy and previous radiation therapy to the chest
- •a history of CHF/MI or other significant cardiac history within the last six months
研究者
Goetz Kloecker
Associate Professor
University of Louisville
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or LymphomasChildhood Burkitt LymphomaChildhood Central Nervous System Germ Cell TumorChildhood Diffuse Large Cell LymphomaChildhood Grade III Lymphomatoid GranulomatosisChildhood Immunoblastic Large Cell LymphomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood Grade III Lymphomatoid GranulomatosisRecurrent Childhood Large Cell LymphomaRecurrent Childhood Liver CancerRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood Malignant Germ Cell TumorRecurrent Childhood MedulloblastomaRecurrent Childhood RhabdomyosarcomaRecurrent Childhood Small Noncleaved Cell LymphomaRecurrent Childhood Soft Tissue SarcomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway GliomaRecurrent Colon CancerRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorRecurrent MelanomaRecurrent Nasopharyngeal CancerRecurrent NeuroblastomaRecurrent OsteosarcomaRecurrent Wilms Tumor and Other Childhood Kidney TumorsRecurrent/Refractory Childhood Hodgkin LymphomaUnspecified Childhood Solid Tumor, Protocol SpecificNCT00101270National Cancer Institute (NCI)24
终止
1 期
Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)Myelodysplastic SyndromesLeukemiaAcute Myeloid LeukemiaNCT00480987M.D. Anderson Cancer Center27
终止
2 期
Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung CancerSmall Cell Lung CancerNCT00316433Swedish Medical Center24
已完成
2 期
The Efficacy of Oxaliplatin Plus S-1 for Treatment of Gastric CancerStomach NeoplasmsNCT01531452Chinese Academy of Medical Sciences43
撤回
3 期
Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma PatientsHepatic Neoplasm MalignantNCT01245582Sanofi